Maintenance treatment for advanced ovarian cancer after first chemotherapy
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study tests a new maintenance therapy for people with advanced ovarian, fallopian tube, or primary peritoneal cancer who have finished their first round of chemo and are showing good response. The goal is to see if this treatment helps delay the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You have advanced (stage III or IV) ovarian, fallopian tube, or primary peritoneal cancer
- You have completed 6 to 9 cycles of first-line platinum-based chemo (or at least 4 cycles if stopped early due to side effects)
- Your cancer responded well to chemo (either complete or partial response) and your CA125 levels have normalized or dropped significantly
- You have not taken a PARP inhibitor before (like olaparib, niraparib, or similar drugs)
- You are able to perform daily activities with minimal help (ECOG 0-1)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two oral medications given after your first round of chemotherapy. The goal is to see if taking these drugs regularly can keep the cancer from coming back.
This trial tests whether a maintenance treatment (fluzoparil and apatinib) can help keep ovarian cancer from coming back after successful platinum-based chemotherapy. It is for women whose cancer either came back within 6 months of their last treatment (platinum-resistant) or more than 6 months later (platinum-sensitive) and who have responded to further chemo.
This trial compares two drug combinations (fluzoparib plus bevacizumab versus olaparib plus bevacizumab) given after initial chemotherapy to keep advanced ovarian cancer from coming back. Participants must have a specific genetic marker (HRD-positive) and have responded well to their first treatment.
This trial tests if adding bevacizumab (a drug that blocks blood vessel growth) or a special diet to fluzoparib (a PARP inhibitor) works better than fluzoparib alone for women with advanced ovarian cancer whose tumors have specific genetic features (HRD-positive or HRD-negative). It is for patients who have already responded well to initial chemotherapy.
This trial tests whether adding fluzoparib to bevacizumab can help control ovarian cancer that has returned after earlier PARP inhibitor (PARPi) treatment. It may help shrink tumors or slow the cancer from growing again.
This trial tests whether a combination of medications (hydroxychloroquine, everolimus, and others) can help keep ovarian cancer from coming back after successful platinum chemotherapy plus Avastin. It is for people whose cancer responded well to their most recent chemo and who can continue Avastin maintenance.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.